Observational studyClinical and experimental medicine2025
Prognostic value of whole lymph node molecular analysis in colorectal cancer: a prospective multicenter study.
Observational study in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Lymph node (LN)-negative colorectal cancer (CRC) patients may be understaged by conventional hematoxylin and eosin for its low sensitivity for detecting LN micrometastasis (LNM). The one-step nucleic acid amplification assay (OSNA) has shown superior performance in detecting LNM. To date, OSNA studies in CRC have analyzed part of the LN tissue with OSNA and part with H&E, introducing a tissue allocation bias for LNM detection. We aimed to evaluate the prognostic significance of the whole LN molecular analysis using OSNA in CRC patients. This prospective multicenter study analyzed LNs from stage I-III CRC by both cytology smears (CS) and OSNA, the latter analyzing the whole LN tissue and reported as the Total Tumor Load (TTL). X-tile software was used to determine the optimal TTL threshold. Cox proportional hazard and Kaplan-Meier estimation were used to assess the prognostic significance of TTL for both cancer-specific survival (CSS) and recurrence-free survival (RFS). 158 CRC patients were included, with 156 eligible for survival analysis. A TTL of 15,000 copies/µL was identified as the optimal cut-off, stratifying CRC patients into low and high risk for both CSS and RFS (P < 0.05). Conversely, CS pN-positive patients with TTL ≤ 15,000 copies/μL had comparable long-term outcomes to CS pN-negative patients (P > 0.05). A TTL threshold of > 15,000 copies/μL has prognostic value as it identifies CRC patients with significantly reduced CSS and RFS. The clinical implementation of the whole LN analysis by OSNA allows accurate patient risk stratification and optimizes postsurgical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.